Form 4 for BEAM Beam Therapeutics Inc.
Accepted 2023-07-25 00:00:00 ET · period of report 2023-07-21 · accession 0000950170-23-034518 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2023-07-25 | 2023-07-21+ | BEAM | Ciaramella Giuseppe | Pres, CSO | M - OptEx | $7.22 | +92.5K | 49.5K | New | +$667.8K |
| DMT | 2023-07-25 | 2023-07-21+ | BEAM | Ciaramella Giuseppe | Pres, CSO | S - Sale+OE | $32.06 | -156.5K | 48.2K | -76% | -$5.02M |
| DMT | 2023-07-25 | 2023-07-21+ | BEAM | Ciaramella Giuseppe | Pres, CSO | M - OptEx | $0.00 | -92.5K | 19.0K | -83% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-07-21 | M | A | 21,846 | $7.22 | 203,574 | D | — | — | |
| 2 | Common | Common Stock | 2023-07-21 | M | A | 69,438 | $7.22 | 181,728 | D | — | — | |
| 3 | Common | Common Stock | 2023-07-24 | S | D | 1,206 | $32.01 | 48,250 | D | — | — | (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $32.00 to $32.095, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 4 | Common | Common Stock | 2023-07-24 | M | A | 1,206 | $7.22 | 49,456 | D | — | — | |
| 5 | Common | Common Stock | 2023-07-21 | S | D | 155,324 | $32.06 | 48,250 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $32.00 to $32.11, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 6 | Derivative | Stock Option (Right to Buy) | 2023-07-21 | M | D | 21,846 | $0.00 | 1,457 | D | $7.22 · — to 2029-05-31 | 21,846 Common Stock | (F5) This stock option vests as to 25% on the first anniversary of the vesting commencement date, October 1, 2019, and at a rate of 2.78% each month thereafter until the option is fully vested. |
| 7 | Derivative | Stock Option (Right to Buy) | 2023-07-21 | M | D | 69,438 | $0.00 | 20,208 | D | $7.22 · — to 2029-05-17 | 69,438 Common Stock | (F5) This stock option vests as to 25% on the first anniversary of the vesting commencement date, October 1, 2019, and at a rate of 2.78% each month thereafter until the option is fully vested. |
| 8 | Derivative | Stock Option (Right to Buy) | 2023-07-24 | M | D | 1,206 | $0.00 | 19,002 | D | $7.22 · — to 2029-05-17 | 1,206 Common Stock | (F5) This stock option vests as to 25% on the first anniversary of the vesting commencement date, October 1, 2019, and at a rate of 2.78% each month thereafter until the option is fully vested. |